POST

FDA Will Review Obesity Drug Qnexa Again

After turning down its submission for approval two years ago, the Food and Drug Administration (FDA) is now concerned over associations of obesity drug Qnexa with birth defect risks and its incidence on the heart. Unlike last year when the agency had only 1 year’s data to study the FDA Advisory Panel (Endocrinology and Metabolic Read more